Core Viewpoint - Bavarian Nordic A/S has submitted clinical data to the European Medicines Agency (EMA) to expand the use of its MVA-BN® mpox and smallpox vaccine to include children aged 2-11 years, based on positive results from a clinical trial showing comparable safety and immune responses between children and adults [1][2]. Group 1: Clinical Trial Results - The submission is based on positive topline results from a Phase 2 clinical trial (NCT06549530) involving 227 children aged 2-11 years and 224 adults, demonstrating non-inferiority of immune response and a similar safety profile between the two age groups after vaccination with two standard doses of the MVA-BN vaccine [2]. - The trial was co-funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and conducted in the Democratic Republic of Congo (DRC) and Uganda, both of which have reported cases of mpox during recent outbreaks [2]. Group 2: Regulatory and Market Implications - Following the review of these data by the EMA, the marketing authorization for MVA-BN could be expanded to include individuals aged 2 years and older later in 2026 [3]. - The submission to a WHO-recognized authority like the EMA is seen as a significant step towards protecting children globally, with the potential for other regulatory authorities to follow suit if the vaccine is approved for younger age groups [4]. Group 3: Public Health Context - The CEO of Bavarian Nordic emphasized the importance of expanding vaccine access for vulnerable populations, particularly children, who have been disproportionately affected by mpox, especially in the context of other health challenges like malnutrition and HIV [4]. - A medical expert from the University of Kinshasa noted that children aged 2 to under 12 years make up nearly one-third of the population in the DRC and are significantly impacted by complications from mpox, highlighting the need for vaccination in this age group to control outbreaks and reduce health burdens [4]. Group 4: Vaccine Information - MVA-BN, or Modified Vaccinia Ankara-Bavarian Nordic, is the only non-replicating mpox vaccine approved in the USA, Switzerland, Singapore, Mexico, Canada, and the EU/EAA, originally developed as a smallpox vaccine to ensure safety for immunocompromised individuals [5]. - The vaccine has since been approved for use in the general population aged 12 years and older who are at risk of mpox or smallpox [5]. Group 5: Company Overview - Bavarian Nordic is a global vaccine company focused on improving health and saving lives through innovative vaccines, serving as a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness [6].

Core Viewpoint - Valneva SE is actively participating in the 26th World Vaccine Congress, showcasing its advancements in vaccine development, particularly for chikungunya, and engaging with partners in the industry [1][5]. Group 1: Company Participation and Events - Valneva will be represented by its CEO Thomas Lingelbach and senior executives at the World Vaccine Congress from March 31 to April 2, 2026 [1]. - On April 1, 2026, Susanne Eder-Lingelbach will present updates on chikungunya vaccine development, focusing on Phase IV and real-world evidence studies [2]. - Valneva's Chief Medical Officer, Dr. Juan Carlos Jaramillo, will participate in a panel discussion on chikungunya and mosquito-borne vaccines on the same day [4]. Group 2: Chikungunya Vaccine Campaign - Valneva and Instituto Butantan have launched a pilot vaccination campaign for the chikungunya vaccine IXCHIQ® in Brazil, with over 12,000 individuals vaccinated to assess the vaccine's effectiveness and safety in real-world conditions [3]. Group 3: Chikungunya Overview - Chikungunya virus (CHIKV) is a mosquito-borne disease causing significant health issues, with over 3.7 million cases reported in the Americas from 2013 to 2023 [6]. - The World Health Organization (WHO) has identified chikungunya as a major public health concern, with its impact expected to grow due to climate change [6]. Group 4: Company Background - Valneva is a specialty vaccine company focused on developing, manufacturing, and commercializing vaccines for infectious diseases, addressing unmet medical needs [7]. - The company has a strong track record in advancing vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [8].

Core Viewpoint - Valneva SE is actively participating in the 26th World Vaccine Congress, showcasing its advancements in vaccine development, particularly for chikungunya, and engaging with partners in the industry [1][5]. Group 1: Company Participation and Events - Valneva will be represented by its CEO Thomas Lingelbach and senior executives at the World Vaccine Congress from March 31 to April 2, 2026 [1]. - On April 1, 2026, Susanne Eder-Lingelbach will present updates on chikungunya vaccine development, focusing on Phase IV and real-world evidence studies [2]. - Valneva's Chief Medical Officer, Dr. Juan Carlos Jaramillo, will participate in a panel discussion on chikungunya and mosquito-borne vaccines on the same day [4]. Group 2: Chikungunya Vaccine Campaign - Valneva and Instituto Butantan have launched a pilot vaccination campaign for the chikungunya vaccine IXCHIQ® in Brazil, with over 12,000 individuals vaccinated to assess the vaccine's effectiveness and safety in real-world conditions [3]. Group 3: Industry Context - Chikungunya virus (CHIKV) is a significant public health concern, with over 3.7 million cases reported in the Americas between 2013 and 2023, and its economic impact is expected to grow due to climate change [6]. - The World Health Organization (WHO) has identified chikungunya as a major public health problem, emphasizing the need for effective vaccines [6]. Group 4: Company Overview - Valneva is a specialty vaccine company focused on developing, manufacturing, and commercializing vaccines for infectious diseases, addressing unmet medical needs [7]. - The company has a strong track record in advancing vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [8]. - Revenues from its commercial business support the advancement of its vaccine pipeline, which includes candidates for Lyme disease and Shigella, among others [9].

Core Insights - Vaxcyte, Inc. has completed enrollment in two pivotal Phase 3 trials (OPUS-1 and OPUS-2) for its next-generation pneumococcal conjugate vaccine, VAX-31, which aims to establish a new standard of care for adult pneumococcal vaccines [1][2][3] Group 1: OPUS-1 Phase 3 Study - The OPUS-1 trial is a noninferiority study with approximately 4,000 participants, evaluating the safety, tolerability, and immunogenicity of VAX-31 compared to existing vaccines PCV21 and PCV20 [1][3] - The study targets healthy, pneumococcal-naïve adults aged 50 years and older, with a separate cohort of adults aged 18-49 years [3][4] - Results from the OPUS-1 trial are expected in the fourth quarter of 2026, supporting a planned Biologics License Application (BLA) submission [1][2] Group 2: OPUS-2 Phase 3 Study - The OPUS-2 trial, now fully enrolled with approximately 1,300 adults, evaluates the concomitant administration of VAX-31 with a seasonal influenza vaccine [1][8] - This study aims to provide real-world performance insights and is designed to inform potential post-licensure outcomes studies [8] - Results from the OPUS-2 trial are anticipated in the first half of 2027 [1][2] Group 3: Immunogenicity and Safety - The primary immunogenicity objective for OPUS-1 is to demonstrate noninferiority of VAX-31 compared to PCV21 and PCV20 for 28 shared serotypes in adults aged 50 years and older [5][11] - Key secondary objectives include assessing the superiority of VAX-31 for unique serotypes and comparing immune responses across different age groups [11][14] - Safety and tolerability will be monitored for six months following vaccination in both trials [4][9] Group 4: VAX-31 Vaccine Profile - VAX-31 is a 31-valent pneumococcal conjugate vaccine designed to cover approximately 95% of invasive pneumococcal disease (IPD) and 88% of pneumococcal pneumonia in adults aged 50 and older [16] - The vaccine aims to provide incremental coverage improvements over current standard-of-care vaccines, potentially increasing IPD coverage by 14-34% and pneumonia coverage by 19-31% [16] - VAX-31 has received Breakthrough Therapy designation from the FDA for the prevention of pneumonia in addition to IPD, based on positive Phase 1/2 study results [17]

Core Insights - Vaxcyte's VAX-31 has shown promising results in a Phase 1/2 study, demonstrating robust immune responses and a safety profile comparable to Prevnar 20® [1][2][3] - The vaccine is designed to cover approximately 95% of invasive pneumococcal disease (IPD) and 88% of pneumococcal pneumonia in U.S. adults aged 50 and older, potentially offering broader coverage than current vaccines [1][8] Study Results - VAX-31 was well tolerated across all doses, with a safety profile similar to PCV20, and no serious adverse events related to the vaccine were reported [2][10] - The High Dose of VAX-31 met or exceeded non-inferiority criteria for all 20 serotypes common with PCV20 and demonstrated superior immune responses for 11 additional serotypes unique to VAX-31 [2][10] Immunogenicity Findings - VAX-31 demonstrated high geometric mean concentrations (GMCs) of immunoglobulin G (IgG) across all 31 serotypes, consistent with opsonophagocytic activity (OPA) results [10] - At the High Dose, 18 of 20 serotypes showed greater immune responses compared to PCV20, with seven achieving statistically significant higher responses [2][10] Future Development - Based on the study results, VAX-31 has advanced into a comprehensive Phase 3 adult program, with topline data expected in Q4 2026 [1][3] - The OPUS Phase 3 trials aim to support a Biologics License Application, contingent on study outcomes [3][10] About Pneumococcal Disease - Pneumococcal disease, caused by Streptococcus pneumoniae, leads to significant morbidity and mortality, particularly in older adults and young children, highlighting the need for broader-spectrum vaccines [7][8] - The CDC identifies drug-resistant strains of Streptococcus pneumoniae as a serious threat, underscoring the urgency for effective vaccination strategies [7]

Core Insights - Valneva reported total product sales of EUR 157.9 million for the year, a decrease of 3.3% year over year, attributed mainly to a planned reduction in third-party product sales and adverse currency impacts [1][5] - The company achieved total revenues exceeding EUR 170 million in 2025, with a cash position of nearly EUR 110 million and a more than 20% reduction in operating cash burn [2][5] - The upcoming phase 3 data for the Lyme disease vaccine candidate VLA15, partnered with Pfizer, is highlighted as a significant near-term value driver [3][6] Financial Performance - Valneva's total revenues for 2025 were reported at over EUR 170 million, with product sales around EUR 158 million and an operating loss of EUR 82.1 million [5][21] - The company guided for 2026 product sales between EUR 145 million and EUR 160 million, and total revenues of EUR 155 million to EUR 170 million, indicating a forecasted decline mainly due to planned cuts in third-party sales [5][22] - Operating cash burn was reduced by over 20%, reflecting disciplined cash management [2][5] Product and Pipeline Highlights - IXIARO sales grew to EUR 98.4 million, a 4.6% increase year over year, while IXCHIQ reached EUR 8.4 million, driven by a pilot campaign in Brazil [4][9] - Third-party product sales fell to EUR 19.2 million, down from EUR 33.2 million, due to the termination of distribution contracts [4][9] - The Lyme disease vaccine VLA15 is undergoing a pivotal phase 3 trial with results expected in the first half of 2026 [6][10] Research and Development - R&D expenses increased to EUR 85.3 million, driven by higher spending on the phase 2 Shigella program and increased investment in IXCHIQ [20] - The company is also focusing on the chikungunya vaccine IXCHIQ, with a pilot vaccination campaign initiated in Brazil [15][16] - Progress is being made on the Shigella candidate S4V2, with ongoing phase 2 studies and data expected around mid-2026 [17] Strategic Outlook - Management emphasized a focus on self-sustainability, particularly if the Lyme vaccine is approved, aiming for potential profitability [22] - The company is refining its commercial strategy and expanding partnerships for its vaccine portfolio, particularly in low- and middle-income countries [15][16]

Core Insights - Valneva SE reported its audited consolidated financial results for the year ended December 31, 2025, confirming its financial guidance for 2026 and filing its annual report with regulatory authorities [1][3][43] Financial Performance - Total revenues for 2025 were €174.7 million, an increase from €169.6 million in 2024, driven by product sales and collaboration agreements [6][7][24] - Product sales amounted to €157.9 million, down from €163.3 million in 2024, reflecting a planned reduction in third-party sales by 42.3% [7][10] - The net loss for 2025 was €115.2 million, compared to a net loss of €12.2 million in 2024, primarily due to the absence of a significant gain from the sale of a Priority Review Voucher in the previous year [7][32] - Operating cash burn improved to €52.9 million in 2025 from €67.2 million in 2024, indicating better cost management [6][34] Product Sales Breakdown - IXIARO®/JESPECT® sales increased by 4.6% to €98.4 million, benefiting from growth in the travel market [11] - DUKORAL® sales were €31.9 million, slightly down from €32.3 million in 2024, affected by currency fluctuations and distribution changes [12] - IXCHIQ® sales rose to €8.4 million from €3.7 million in 2024, supported by its launch in several European countries [13] Clinical Developments - The Phase 3 data readout for the Lyme disease vaccine candidate VLA15 is expected in the first half of 2026, which could significantly impact the company's future [4][15] - Valneva is also advancing its Shigella vaccine candidate S4V2, with Phase 2 results anticipated mid-2026 [21][22] 2026 Financial Guidance - Total revenues for 2026 are projected to be between €155 million and €170 million, with product sales expected to range from €145 million to €160 million [6][7] - The guidance reflects continued growth in established brands but anticipates a decline in third-party sales [7][10] Cash Position and Management - The company ended 2025 with a strong cash position of €109.7 million, down from €168.3 million in 2024, but with improved financial flexibility following successful debt refinancing [6][37] - Disciplined cash management will remain a priority, with expectations for further reductions in operating cash burn in 2026 [7][34]

Financial Data and Key Metrics Changes - Revenue for the full year 2025 was $237.3 million, a significant increase from $28.7 million in 2024, primarily driven by government contracts and the Dynavax collaboration [20] - Cash equivalents and investments at the end of the fourth quarter were $63.8 million, with an expected cash runway into the second quarter of 2027 [20][21] Business Line Data and Key Metrics Changes - The partnership with Dynavax for the oral COVID-19 vaccine candidate includes a $25 million upfront payment and a $5 million equity investment, with potential future payments totaling up to $700 million [5][7] - The oral norovirus vaccine candidate has shown promising results in clinical studies, with significant increases in IgA levels in both serum and breast milk [14][15][16] Market Data and Key Metrics Changes - The collaboration with Dynavax, now a Sanofi company, is expected to enhance the company's market position in the vaccine space [6][7] - The ongoing phase 2B trial of the oral COVID-19 vaccine candidate is crucial for addressing the ongoing need for next-generation solutions in the context of COVID-19 [10][11] Company Strategy and Development Direction - The company is focused on managing financial resources effectively, pursuing strategic partnerships, and reducing operating costs to enhance cash runway [8][21] - Future priorities include executing data collection for the COVID-19 clinical trial and securing partnerships for the norovirus program [22] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the potential of both the COVID-19 and norovirus oral vaccine programs to provide public health benefits and create shareholder value [22] - The company is committed to realizing the value of its oral pill vaccine platform, which is seen as a disruptive technology in the vaccination landscape [22] Other Important Information - The company has entered into a lease termination agreement to reduce operating expenses, allowing for a more focused allocation of financial resources [5][8] - The results from the 400-participant sentinel cohort of the COVID-19 trial are expected to be reported in early Q2 2026, with the larger KP2 cohort data anticipated in Q4 2026 [11][22] Q&A Session Summary Question: Delay in 400-person sentinel cohort data - Management acknowledged a slight delay in reporting the 400-person sentinel cohort data, now expected in early Q2 instead of late Q1, due to interactions with BARDA [26][28] Question: Expectations for sentinel data and follow-up - The 400-person cohort will provide safety data, while the 5,000-person KP2 cohort will offer efficacy insights, with results expected in Q4 2026 [29][31] Question: Decision points after sentinel data - The decision-making process for next steps post-sentinel data will involve both BARDA and Dynavax, with Vaxart overseeing the Phase 2B trial [35][36] Question: Regulatory input on norovirus candidate - Discussions with the FDA regarding endpoints for the next phase 2 study of the norovirus candidate are ongoing, with a focus on safety and immunogenicity [42][43]

Core Insights - Bavarian Nordic A/S reported its annual results for 2025, confirming strong preliminary results and indicating a strategic transformation towards growth in the Travel Health business [2][4][5] Financial Performance - The company achieved DKK 6,244 million in revenue for 2025, exceeding the latest guidance of approximately DKK 6,000 million [5][7] - Revenue breakdown includes DKK 3,105 million from Public Preparedness, DKK 2,963 million from Travel Health, and DKK 176 million from other revenue [5] - EBITDA excluding other net operating income was DKK 1,732 million, resulting in an EBITDA margin of 28%, surpassing the guidance of approximately 26% [5][9] - Including other net operating income of DKK 810 million, the EBITDA margin increased to 41%, compared to the guidance of approximately 40% [5][9] 2026 Outlook - For 2026, Bavarian Nordic expects revenue between DKK 5,000 million and DKK 5,200 million, with an EBITDA margin of approximately 25% [10][11] - Revenue from Travel Health is projected to be around DKK 3,000 million, while Public Preparedness is expected to generate DKK 1,800 million to DKK 2,000 million [12][11] - The company anticipates a more normalized year in 2026 without the impact of ongoing outbreaks, aligning with mid-term growth ambitions [12] Strategic Developments - In January 2026, Bavarian Nordic initiated a share buy-back program for up to DKK 500 million, with the first tranche of DKK 150 million completed in February [8] - The company entered an agreement with Eurofarma for exclusive rights to sell and distribute its chikungunya vaccine in Brazil [8] - A new order valued at USD 22.5 million was secured from the Public Health Agency of Canada for mpox and smallpox vaccines, increasing secured orders for 2026 to approximately DKK 1,400 million [8] - A strategic partnership with Serum Institute of India was expanded to include a contract manufacturing agreement for the chikungunya vaccine [8] Leadership Changes - Paul Chaplin, the current CEO, will step down later in 2026, marking a change in leadership for the company [2][8]

Core Viewpoint - Valneva SE, a specialty vaccine company, will report its full year 2025 financial results on March 18, 2026, and will host a live webcast to discuss these results and provide a business update [1]. Company Overview - Valneva SE develops, manufactures, and commercializes prophylactic vaccines for infectious diseases, focusing on unmet medical needs with a specialized approach [3]. - The company has a strong track record of advancing multiple vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [4]. Financial and Business Insights - Revenues from Valneva's growing commercial business support the advancement of its vaccine pipeline, which includes the only Lyme disease vaccine candidate in advanced clinical development partnered with Pfizer, and the world's most clinically advanced Shigella vaccine candidate [5].